CRISPR Therapeutics Reports Promising Results for Zugo-cel CAR-T Therapy in Autoimmune Diseases and Blood Cancers
核心洞察
CRISPR Therapeutics' zugo-cel (搜索) CAR-T therapy demonstrated significant clinical improvement in four autoimmune patients, with one systemic lupus erythematosus (搜索) patient achieving drug-free remission through six months.
The therapy showed a 90% overall response rate and 70% complete response rate in relapsed/refractory large B-cell lymphoma (搜索) patients at the 600 million cell dose level.
The company initiated a new Phase 1 trial for immune thrombocytopenic purpura (搜索) and warm autoimmune hemolytic anemia (搜索), and established a collaboration with Lilly (搜索) to evaluate combination therapy.
CRISPR Therapeutics announced encouraging clinical results for zugocaptagene geleucel (搜索) (zugo-cel (搜索)), its investigational allogeneic CAR-T cell therapy targeting CD19 (搜索), showing promising efficacy across both autoimmune diseases and hematologic malignancies. The company provided comprehensive updates on December 22, 2025, highlighting significant clinical improvements in autoimmune patients and strong response rates in blood cancer patients.
Autoimmune Disease Results Show Deep B-Cell Depletion
In the ongoing Phase 1 basket trial for autoimmune rheumatologic diseases, four patients with systemic lupus erythematosus (搜索) (SLE) and immune-mediated necrotizing myopathy have been treated at the 100 million cell dose. As of the December 17, 2025 data cut-off, all patients demonstrated significant clinical improvement at the Day 28 assessment.
The therapy achieved rapid and deep B-cell depletion within the first 1-2 days, which was maintained over the first month of treatment. Notably, the first SLE patient, who was refractory to nine prior therapies with a baseline SLEDAI-2K score of 8, has maintained drug-free DORIS clinical remission through Month 6 following CAR-T therapy.
"Preliminary data from zugo-cel (搜索) in patients with rheumatologic autoimmune diseases have been encouraging, and the therapy has been well tolerated to date," said Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics.
Strong Efficacy in Blood Cancer Patients
In hematologic malignancies, zugo-cel (搜索) demonstrated robust single-agent activity in relapsed or refractory large B-cell lymphoma (搜索) (LBCL). At the recommended Phase 2 dose of 600 million cells, 10 patients with R/R LBCL showed an overall response rate of 90% (9/10) and a complete response rate of 70% (7/10). Among patients who completed 12 months of follow-up, 67% (2/3) remained in complete response at the 12-month evaluation.
The therapy showed peak mean CAR-T cell expansion of approximately 1,700 cells/μL at the recommended Phase 2 dose, representing approximately four-fold higher expansion compared with patients receiving 300 million cells. A total of 39 patients have been treated across all four dose levels in the Phase 1/2 trial.
Safety Profile and Dose Considerations
Treatment was well-tolerated across both indications. No high-grade cytokine release syndrome (CRS) or immune-effector cell-associated neurotoxicity syndrome (ICANS) was observed at the 100 million cell dose used in autoimmune trials. At the higher 600 million cell dose for LBCL patients, rates of Grade 3 CRS, ICANS, and serious infections were 17%, 17%, and 8%, respectively, among all LBCL patients treated at this dose level (n=12).
Expanding Clinical Development
CRISPR Therapeutics has initiated an additional Phase 1 basket trial for zugo-cel (搜索) in refractory primary immune thrombocytopenic purpura (搜索) (ITP) and warm autoimmune hemolytic anemia (搜索) (wAIHA). The company also announced a collaboration and clinical supply agreement with Lilly (搜索) to evaluate zugo-cel in combination with pirtobrutinib for aggressive B-cell lymphomas.
Technology Platform and Mechanism
Zugo-cel (搜索) is an off-the-shelf allogeneic CAR-T therapy that utilizes CRISPR Cas9 for targeted gene knockout and CAR insertion for immune evasion and enhanced T effector cell potency. The therapy targets CD19 (搜索) and is administered following standard lymphodepletion with fludarabine and cyclophosphamide without the need for HLA matching.
The company expects to provide additional updates across autoimmune disease and hematological malignancies in the second half of 2026. Clinical trials remain ongoing across multiple indications, with positive data supporting advancement into Phase 2 portions of existing studies.